Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET

Company Participants

Christine Cassiano - CCO

David Chang - President and CEO

Rafael Amado - EVP, Research & Development and CMO

Eric Schmidt - CFO

Conference Call Participants

Andrea Tan - Goldman Sachs

Michael Yee - Jefferies

Tyler Van Buren - Cowen

Asthika Goonewardene - Truist

Raju Prasad - William Blair

Reni Benjamin - JMP Securities

Mark Breidenbach - Oppenheimer

John Newman - Canaccord Genuity

Michael Schmidt - Guggenheim Partners

Luca Issi - RBC Capital Markets

Jason Gerberry - Bank of America

Kalpit Patel - B. Riley

David Dai - SMBC

Jack Allen - Baird

Brian Cheng - JPMorgan

Robert Burns - H.C. Wainwright

Dane Leone - Raymond James

Ben Burnett - Stifel

Operator

Hello, and thank you for standing by, and welcome to Allogene Therapeutics Third Quarter of 2022 Conference Call. [Operator Instructions] Please be aware that today's conference call is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

Thank you, operator, and welcome to our Q3 call. After market close, we issued a business update and financial results press release for the third quarter of 2022. This press release and today's webcast are available on our website. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many as possible.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capability and 2022 financial guidance, among other things.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.

I'll now turn the call over to David.

David Chang

Thank you, Christine, and good afternoon. I will start today's call focused on our most important milestone, the initiation of our Phase 2 trial with ALLO-501A for the treatment of relapsed or refractory large B-cell lymphoma. Advancing our off-the-shelf allogeneic CD19 CAR T product candidate to a Phase 2 trial brings us one step closer to making this potentially life-saving therapy more readily available to the patients.